PharmaCyte Biotech, Inc.
PMCB
$1.19
$0.043.48%
NASDAQ
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -16.57% | -13.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.24% | -12.77% | |||
| Operating Income | 13.24% | 12.77% | |||
| Income Before Tax | -107.22% | -106.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -107.22% | -106.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -107.22% | -106.27% | |||
| EBIT | 13.24% | 12.77% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -106.66% | -109.69% | |||
| Normalized Basic EPS | 21.94% | 121.28% | |||
| EPS Diluted | -106.66% | -109.69% | |||
| Normalized Diluted EPS | 21.94% | 121.28% | |||
| Average Basic Shares Outstanding | -8.86% | -2.92% | |||
| Average Diluted Shares Outstanding | -8.86% | -2.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||